Bayer Schering Pharma AG, Germany, announced that data from Phase I and II studies evaluating two of the company's late-stage pipeline cancer treatments AlpharadinTM (radium-223 chloride) and regorafenib (BAY 73-4506) will be presented at the 35th European Society for Medical Oncology (ESMO) Congress, October 8-12, 2010, in Milan, Italy. Alpharadin is currently in a global Phase III clinical trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) whose cancer has spread to the bone. The primary endpoint of the Phase III trial is overall survival...
More...
More...